EGFR and colorectal carcinoma: Combining standard chemotherapy with inhibitors of ABC drug transporters and combining EGFR-targeted therapy with inhibitors of c-MET can overcome drug resistance in preclinical models of advanced CRC, however; further clinical studies are needed to evaluate the clinical significance of these combination therapies in enhancing patient outcomes.